In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Motus Gi Holdings (MOTS – Research Report), with a price target of $11.00. The company’s shares closed last Friday at $3.93.
According to TipRanks, Chen is an analyst with an average return of -6.7% and a 36.07% success rate. Chen covers the Healthcare sector, focusing on stocks such as Prophase Labs, Veru, and Co-Diagnostics.
Currently, the analyst consensus on Motus Gi Holdings is a Strong Buy with an average price target of $10.50, a 167.18% upside from current levels. In a report released on August 12, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
MOTS market cap is currently $10.82M and has a P/E ratio of -0.51.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motus GI Holdings, Inc. is a medical technology company, which is dedicated to improving endoscopy outcomes and experiences. It engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company was founded in September, 2016 and is headquartered in Fort Lauderdale, FL.
Read More on MOTS:
- H.C. Wainwright Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
- Prophase Labs (PRPH) Gets a Buy from H.C. Wainwright
- H.C. Wainwright Keeps Their Buy Rating on Aslan Pharmaceuticals (ASLN)
- H.C. Wainwright Keeps Their Buy Rating on Kala Pharmaceuticals (KALA)
- Wall Street Analysts Are Bullish on Top Materials Picks
